Updates are available Correction dated 2024-01-08
Click to view Correction: https://doi.org/10.1038/s41416-023-02521-6
-
Authors
Stögbauer, Fabian http://orcid.org/0000-0002-8897-5165
Beck, Susanne http://orcid.org/0000-0002-2652-8722
Ourailidis, Iordanis http://orcid.org/0000-0001-6783-5617
Hess, Jochen http://orcid.org/0000-0003-3493-1711
Poremba, Christopher
Lauterbach, Maren
Wollenberg, Barbara
Buchberger, Anna Maria Stefanie
Jesinghaus, Moritz
Schirmacher, Peter
Stenzinger, Albrecht
Weichert, Wilko
Boxberg, Melanie
Budczies, Jan http://orcid.org/0000-0002-6668-5327
- License Information
-
More Information
Article History
Received: 4 May 2022
Revised: 12 March 2023
Accepted: 16 March 2023
First Online: 12 April 2023
Change Date: 8 January 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41416-023-02521-6
Competing interests
: PS: Speaker’s fees: AstraZeneca, Incyte, Janssen. Advisory Boards: BMS, MSD, AstraZeneca, Roche. Funding for research: Roche, Chugai, BMS, Novartis. AS: Advisory Board/Speaker’s Bureau: Astra Zeneca, AGCT, Bayer, BMS, Eli Lilly, Illumina, Janssen, MSD, Novartis, Pfizer, Roche, Seattle Genetics, Takeda, Thermo Fisher. Grants: Bayer, BMS, Chugai, Incyte. WW: Advisory Boards and speaker’s fees: Roche, MSD, BMS, AstraZeneca, Pfizer, Merck, Lilly, Boehringer, Novartis, Takeda, Bayer, Amgen, Astellas, Eisai, Illumina, Siemens, Agilent, ADC, GSK and Molecular Health. Funding for research: Roche, MSD, BMS and AstraZeneca. MB: Funding through Deutsche Krebshilfe (German Cancer Aid). Advisory Board and speaker´s fee: BMS, MSD. Funding: BMS. JB: Funding through Deutsche Krebshilfe (German Cancer Aid). The remaining authors declare no competing interests.
: All analyses were conducted in accordance with the Declaration of Helsinki and the TCGA policies (ExternalRef removed).
